Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520998 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Alkahest.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03520998 is a Phase 2 study that has completed, run by Alkahest. The registered enrollment target is 47 participants.
The verdict
NCT03520998, a Phase 2 study, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.
Interventions
- DRUG GRF6019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520998
The ClinicalTrials.gov registry entry for NCT03520998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRF6019 is the first listed.
NCT03520998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520998 about?
NCT03520998 is a clinical study titled "A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease". This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT03520998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-04-16. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT03520998?
The interventions under investigation include: GRF6019 (DRUG).
Who is sponsoring clinical trial NCT03520998?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.